Document Detail

Rapid screening for Chlamydia trachomatis infection by detecting α-mannosidase activity in urogenital tract specimens.
Jump to Full Text
MedLine Citation:
PMID:  23347393     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Chlamydia trachomatis may cause multiple different urogenital tract disorders, but current non-culture assays for rapid screening of C. trachomatis typically use immunochromatography-based methods. We established another new rapid non-culture method for detection of C. trachomatis based on the measurement of α-mannosidase enzymatic activity in urogenital tract specimens.
METHOD: To evaluate the performance of this method, α-mannosidase activities of C. trachomatis serotype D strain 、 and 29 standard strains related to clinical urogenital pathogens were investigated. Furthermore, 553 urogenital tract specimens were used for clinical assays via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.
RESULTS: Only C. trachomatis was positive for α-mannosidase activity among different types of microbes tested in the research. When prostate fluid specimens, which have some interfering activity, were excluded, the sensitivity and specificity of the enzymatic method were 91.8% (78/85) and 98.3% (409/416), respectively. There were no significant differences (P > 0.05).
CONCLUSIONS: These results showed that α-mannosidase activity could be utilised as a screening marker of C. trachomatis infection.
Ze-yu Wang; Guang-yu Fu; Shan-mei Wang; Dong-chun Qin; Zhong-quan Wang; Jing Cui
Related Documents :
6546883 - Effect of fibroblast-pneumonocyte factor on the synthesis of surfactant phospholipids i...
6085723 - Changes of phenotypic characteristics of variants derived from lewis lung carcinoma dur...
21940203 - Large-scale production of saikosaponins through root culturing of bupleurum falcatum l....
Publication Detail:
Type:  Journal Article     Date:  2013-01-24
Journal Detail:
Title:  BMC infectious diseases     Volume:  13     ISSN:  1471-2334     ISO Abbreviation:  BMC Infect. Dis.     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-06-18     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  100968551     Medline TA:  BMC Infect Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  36     Citation Subset:  IM    
Department of Pathogen Biology, School of Basic Medicine, Zhengzhou University, Zhengzhou, 450001, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chlamydia Infections / diagnosis*
Chlamydia trachomatis / enzymology*,  isolation & purification
Reproducibility of Results
Sensitivity and Specificity
Urogenital System / microbiology*
alpha-Mannosidase / metabolism*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Infect Dis
Journal ID (iso-abbrev): BMC Infect. Dis
ISSN: 1471-2334
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2013 Wang et al.; licensee BioMed Central Ltd.
Received Day: 19 Month: 8 Year: 2012
Accepted Day: 22 Month: 1 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 24 Month: 1 Year: 2013
Volume: 13First Page: 36 Last Page: 36
PubMed Id: 23347393
ID: 3568413
Publisher Id: 1471-2334-13-36
DOI: 10.1186/1471-2334-13-36

Rapid screening for Chlamydia trachomatis infection by detecting α-mannosidase activity in urogenital tract specimens
Ze-yu Wang1 Email:
Guang-yu Fu1 Email:
Shan-mei Wang2 Email:
Dong-chun Qin3 Email:
Zhong-quan Wang1 Email:
Jing Cui1 Email:
1Department of Pathogen Biology, School of Basic Medicine, Zhengzhou University, Zhengzhou, 450001, China
2Department of Clinical Laboratory, Henan Provincial People’s Hospital, Zhengzhou, 450003, China
3Department of Clinical Laboratory, First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, China


C. trachomatis infection is the most common sexually transmitted disease (STD) in the United States [1]. Mounting evidence has indicated that it not only evokes nongonococcal urethritis (NGU), cervicitis, pelvic inflammatory disease (PID), salpingitis, orchitis, and epididymitis, but also increases risk of invasive cervical cancer [2,3] and gives rise to serious reproductive disorders such as infertility [4,5], miscarriage/premature birth/missed miscarriage [6-9], and neonatal conjunctivitis [10].

A large number of methods have been established for screening and diagnosis of C. trachomatis infection [11]. Nevertheless, few of these assays meet the requirements of outpatient diagnosis, especially in terms of sensitivity, specificity, time, and simplicity of operation. Currently, non-culture assays for C. trachomatis screening typically adopt immunochromatography-based methods. Technologies based on chromogenic reactions of specific microbial enzymes have been widely applied in bacterial identification systems and chromogenic media [12-15]. However, no chromogenic assay for detecting C. trachomatis has been made available to date.

Our previous findings [16] suggested that C. trachomatis might have very high α-mannosidase activity. The purpose of the study was to establish a novel screening method for C. trachomatis infection without culture that would be rapid and convenient for use in outpatient clinics.

Ethics statement

All patients were treated in accordance with the Helsinki Declaration on the participation of human subjects in medical research. Ethics approval for the study was obtained from the First Affiliated Hospital Ethics Committee of Zhengzhou University (Approved No. 20100802) and Henan Provincial People’s Hospital Ethics Committee (Approved No. 20100901).


Reference strains and cell lines were obtained from the organisations shown in Table 1.


This study evaluated 553 specimens from clinical patients attending the STD (257, 46.47%) and Gynaecology (296, 53.53%) clinics at the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) and the Henan Provincial People’s Hospital (Zhengzhou, China), respectively. For the 203 male cases, three urethral discharge specimens (151 outpatients, 74.38%) or three prostate massage liquid specimens (52 outpatients, 25.62%) were collected with sterile rayon swabs (Copan, Brescia, Italy). Meanwhile, for the 350 female cases, three cervical secretion specimens (232 outpatients, 66.29%) or three vaginal secretion specimens (118 outpatients, 33.71%) were collected with sterile rayon swabs using vaginal forceps. Three swabs collected for each specimen, were no significant differences in sampling link and randomly used with three methods. None of the patients received any antibiotics one week before sample collection, when samples were taken before diagnosis.

Media, culture and inoculation

Liquid media A (LMA) and liquid media B (LMB) were prepared for mycoplasma culture. The components of LMA were shown in Table 2, but LMB consisted of 50 mg/l phenol red besides LMA components. The media were inoculated with both Ureaplasma urealyticum and Mycoplasma hominis and analyzed by using the colour-changing unit (CCU) method, as previously reported [17]. Once the concentrations of mycoplasma reached 106 CCU/ml in LMB, the cultures of LMA should be immediately stored at 4°C.

Trichomonas vaginalis was obtained after 24 h incubation at 37°C in Trichomonas medium (Oxoid, Basingstoke, UK) supplemented with 8% horse blood and 1,000 units/ml penicillin sodium and 500 mg/ml streptomycin. The collection was stored at 4°C.

All other micro-organisms except C. trachomatis used in the study were inoculated and cultured as described in Table 3. The collections described in Table 3 were resuspended to 0.5 McFarland standards in a sterile solution of 0.9% NaCl and then stored at 4°C.

Enzymatic method

The enzymatic method was based on the substrate of α-D-mannosidase. The substrate solution contained 1.5 mg/ml 6-chloro-3-indolyl-α-D-mannoside (J&K, Shanghai, China), 100 mM citrate buffer (pH 4.0), and 1% Triton X-100. The sample diluent was 0.9% NaCl. The chromogenic reagent contained 0.08% fast violet B salt (J&K, Shanghai, China). Aliquots (50 μl) of substrate solution and chromogenic reagent were added sequentially into sample solutions (extracted from every swab sample with 500 μl sample diluent) or the aforementioned microbial suspensions as well as the chlamydial suspension mentioned in the section called limit of detection (LOD) of the enzymatic method. The result was considered to be positive (OD512 ≧ 0.150) if the colour changed from colourless to red or brown after 15 min of incubation at 37°C; otherwise, the result was considered to be negative (OD512 < 0.150). The suspensions containing bacteria or cells was centrifuged at 5,000 rpm for 5 min, and then OD512 value of the supernatants were measured.

LOD of the enzymatic method

McCoy cells infected with C. trachomatis serovar D were stored at −80°C, and frozen-thawed twice to obtain chlamydial suspension before use. Serial 10-fold dilutions of the chlamydial suspension were inoculated in six duplicate into wells (100 μl/well) of cycloheximide-treated McCoy cell monolayers that had been incubated with MEM medium (Gibco, Grand Island, NY, USA) in a 96-well flat-bottom microtiter plate (Nunc Inc., Roskilde, Denmark) at 37°C under 5% CO2 for 48 h. Inclusion body titers of the chlamydial supernatant were quantified by titrating the number of inclusion-forming units (IFU). The contents of each well were stained with a C. trachomatis direct fluorescent antibody kit (Academy of Military Medical Science, Beijing, China) and examined by microscopy for IFU counts. The average IFU of each dilution culture of three replicate wells was taken as the concentration of C. trachomatis in the corresponding dilution of the chlamydia suspension. Each dilution culture of the other three replicate wells was examined via the enzymatic method after collection to determine the LOD for C. trachomatis of the enzymatic method. 10-1 u/ml α-D-mannosidase (EC3.2.1.24; Sigma, USA) solution was 5-fold serially diluted to 10-4 u/ml. These enzyme solutions fold-diluted were detected via the enzymatic method to determine the LOD for α-D-mannosidase.

Reference method

Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method. The swabs used for culture were dipped directly into incidental transport medium (Copan, Brescia, Italy) and cultured according to the aforementioned method. The cultures were tested using a C. trachomatis direct fluorescent antibody kit. LCR was carried out using the LCx C. trachomatis assay (Abbott Laboratories, Abbott Park, Israel) according to the manufacturer’s instructions. Although culture method has a good specificity, its sensitivity may be influenced by various factors. Therefore, the research adopted an “expanded gold standard” [18-20] described as follows: any positive by either culture or LCR was classified as a true positive, whatever the result of the enzymatic method.


In our developed assay, only C. trachomatis samples tested was positive for α-D-mannosidase activity; but OD512 of both other organisms and cell cultures which were not inoculated with C. trachomatis used in the study was all below 0.100, which fell into the range of negative results negative with 0.150 (OD512) as the cut-off value, even if the reactions were allowed to proceed for 1 h at 37°C. Of the 553 clinical samples, 132 samples were positive with OD512 ranging from 0.161 to 1.955, and 421 samples were negative with OD512 ranging from 0.013 to 0.142. C. trachomatis detection results of 553 cases with culture, LCR and enzymatic method used an expanded gold standard as the reference standard were showed in Table 4. The enzymatic method was least reliable when prostate specimens were used. The sensitivity of the enzymatic method was 91.5% (95% confidence interval [CI], 85.9% to 97.1%), and the specificity of this method was 90.0% (95% CI, 87.3% to 92.7%) (Table 5). The sensitivity and specificity of the LCR were 94.7% (95% CI, 90.2% to 99.2%) and 100% (95% CI, 100.0% to 100.0%), respectively. However, in those specimens other than prostate fluid samples, the sensitivity and specificity of the enzymatic method were 91.8% (95% CI, 86.0% to 97.6%) and 98.3% (95% CI, 97.1% to 99.5%), in the meantime the sensitivity and specificity of the LCR were 95.3% (95% CI, 90.8% to 99.8%) and 100% (95% CI, 100% to 100%) (Table 6), respectively. There were no significant differences in performance between the enzymatic method and the expanded gold standard (P > 0.05).

The result of the chlamydial suspension quantified with 617 IFU/ml was light pink, and might be considered positive (OD512 = 0.162). Meanwhile, the result of the chlamydial suspension was colourless if quantified with 126 IFU/ml, and might be considered negative (OD512 = 0.098). Therefore, the LOD was 617 IFU/ml for C. trachomatis. In addition, the LOD was 10-3 u/ml (OD512 = 0.155) for α-D-mannosidase.


There are various well-known methods for detecting C. trachomatis, including cell culture-, immunology-, molecular biology-, and biochemistry-based methods. Cell culture is complicated to perform and requires experience to produce accurate results, and it also has more stringent requirements for the sampling swabs and transporting before inoculation [21,22]. Therefore, cell culture is rarely used in clinics. Among the available immunological methods, serological tests for the C. trachomatis antibody have significant limitations [23], but methods for C. trachomatis antigen detection (mainly referring to the lipopolysaccharide, LPS), especially immunochromatography-based methods, have been widely used due to their simplicity of operation. There are two ways to extract the LPS antigen for C. trachomatis immunochromatographic assays: heat extraction and acid extraction. Neither of these methods guarantees the full extraction of LPS as an intact antigen, which influences the sensitivity of this method. The biochemical detection of glycogen in C. trachomatis inclusions [24] is greatly affected by Candida spp. that often exist in these specimens and are especially common during the female menstrual cycle and pregnancy. With the increasing glycogen in vaginal epithelial cells, this method may also cause false positives. The detection of C. trachomatis in the United States and Europe has mainly focused on molecular biology methods [25-30]. Although these methods are both high sensitivity and high specificity, it can be challenging for molecular biology methods to meet the requirements of the actual application in clinical screening.

Enzymatic studies of C. trachomatis, especially for enzymes with diagnostic significance, have not been reported in the literature. Previous studies [31] and our research have shown that C. trachomatis secretes extracellular enzymes with high α-D-mannosidase activity. Although some organisms used in the study such as C. albicans have genes encoding α-1,2-mannosidase [32], α-D-mannosidase activity was invisible by naked eyes with 6-chloro-3-indolyl-α-D-mannoside as substrate. This may be because the extracellular α-D-mannosidase from these organisms is much less or the enzyme activity is relatively low. Previous records [31,33-35] on substrates of α-D-mannosidase mainly involved p-nitrophenol-α-D-mannoside and 4-methylumbelliferyl-α-D-mannoside. However, 6-chloro-3-indolyl-α-D-mannoside is a novel chromogenic substrate, and colour reaction of its chromogen is much more sensitive especially in the case of the presence of an azo reagent such as fast violet B salt.

Our results showed that clinical specimens such as urethral discharge, cervical secretions, and vaginal secretions did not interfere with the chromogenic detection of α-D-mannosidase activity to screen for C. trachomatis, although prostate massage liquid produced more false positive results. Some human sperm surface proteins possess α-D-mannosidase activity [36], which may be the reason that prostate specimens produce less reliable results. Serotype D was only one of the most prevalent (11.1%), and no serovar L2 was found in China [37]. Although the results of this study suggested that other serotypes, such as serotypes E, F, G, K, H, J, I, and Ba, at least most of them, might have α-D-mannosidase activity, there seems to be some limitation of tests on C. trachomatis cultures based on only one strain of serotype D. Further studies and more comprehensive clinical evaluations should be conducted due to little research on α-D-mannosidase activity of C. trachomatis. In addition, our studies did not evaluate C. pneumoniae or C. psittaci; the α-D-mannosidase activities of these species should be studied as well.


The present study demonstrated that there were no significant differences between the enzymatic method and the reference method when prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and need for no special equipment. Taken together, these data show that the enzymatic method has great potential as a clinical method for C. trachomatis screening.

Competing interests

The authors declare that they have no competing interests. We are applying for one patent (CN patent 102286608A) relating to the content of the manuscript, and the authors do not have any objection on the patent right of authorship and ownership.

Authors’ contributions

ZYW conceived of the study and designed all the experiments and drafted the manuscript. ZYW, GYF, SMW and DCQ performed the experiments. ZYW and ZQW performed the statistical analysis. ZQW and JC provided valuable insight for designing the study and revising the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

Centers for Disease Control and PreventionSexually transmitted disease surveillance, 2009Year: 2011Atlanta, GA: Centers for Disease Control and Prevention
Madeleine MM,Anttila T,Schwartz SM,Saikku P,Leinonen M,Carter JJ,Wurscher M,Johnson LG,Galloway DA,Daling JR,Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactorsInt J CancerYear: 200712065065510.1002/ijc.2232517096345
Smith JS,Bosetti C,Muñoz N,Herrero R,Bosch FX,Eluf-Neto J,Meijer CJ,Van den Brule AJ,Franceschi S,Peeling RW,Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case–control studyInt J CancerYear: 200411143143910.1002/ijc.2025715221973
Joki-Korpela P,Sahrakorpi N,Halttunen M,Surcel HM,Paavonen J,Tiitinen A,The role of Chlamydia trachomatis infection in male infertilityFertil SterilYear: 2009911448145010.1016/j.fertnstert.2008.06.05118706556
Malik A,Jain S,Rizvi M,Shukla I,Hakim S,Chlamydia trachomatis infection in women with secondary infertilityFertil SterilYear: 200991919510.1016/j.fertnstert.2007.05.07018635168
Blas MM,Canchihuaman FA,Alva IE,Hawes SE,Pregnancy outcomes in women infected with Chlamydia trachomatis: a population-based cohort study in Washington StateSex Transm InfectYear: 20078331431810.1136/sti.2006.02266517344249
Medina M,Moya M,Hidalgo L,Calle A,Terán Eui P,Molecular identification of endocervical Chlamydia trachomatis infectionamong gestations at risk for preterm birth in EcuadorArch Gynecol ObstetYear: 200927991010.1007/s00404-008-0647-y18414882
Silveira MF,Ghanem KG,Erbelding EJ,Burke AE,Johnson HL,Singh RH,Zenilman JM,Chlamydia trachomatis in fection during pregnancy and the risk of preterm birth:a case–control studyInt J STD AIDSYear: 20092046546910.1258/ijsa.2008.00838819541887
Wilkowska-Trojniel M,Zdrodowska-Stefanow B,Ostaszewska-Puchalska I,Redźko S,Przepieść J,Zdrodowski M,The influence of Chlamydia trachomatis infection on spontaneous abortionsAdv Med SciYear: 200954869019403438
Rours IG,Hammerschlag MR,Ott A,De Faber TJ,Verbrugh HA,de Groot R,Verkooyen RP,Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infantsPediatricsYear: 200821e321e32618245405
Black CM,Current methods of laboratory diagnosis of Chlamydia trachomatis infectionsClin Microbiol RevYear: 1997101601848993862
Manafi M,Fluorogenic and chromogenic enzyme substrates in culture media and identification testsInt J Food MicrobiolYear: 199631455810.1016/0168-1605(96)00963-48880296
Orenga S,James AL,Manafi M,Perry JD,Pincus DH,Enzymatic substrates in microbiologyJ Microbiol MethodsYear: 20097913915510.1016/j.mimet.2009.08.00119679151
Van Winkelhoff AJ,Clement M,De Graaff J,Rapid characterization of oral and nonoral pigmented Bacteroides species with the ATB anaerobes ID systemJ Clin MicrobiolYear: 198826106310653290235
Wohlsen TD,Comparative evaluation of chromogenic agar CM1046 and mFC agar for detection of E. coli and thermotolerant coliform bacteria from water samplesLett Appl MicrobiolYear: 20115315516010.1111/j.1472-765X.2011.03086.x21585405
Wang ZY,Kou J,Cui J,Wang ZQ,Chlamydia diagnosis method and reagentYear: 2011China: CN patent 102286608A
Taylor-Robinson D,Thomas M,Dawson PL,The isolation of T-mycoplasmas from the urogenital tract of bullsJ Med MicrobiolYear: 1969252753310.1099/00222615-2-4-5275404806
Berg ES,Anestad G,Moi H,Størvold G,Skaug K,False- negative results of a ligase chain reaction assay to detect Chlamydia trachomatis due to inhibitors in urineEur J Clin Microbiol Infect DisYear: 19971672773110.1007/BF017092529405941
Jang D,Sellors JW,Mahony JB,Pickard L,Chernesky MA,Effects of broadening the gold standard on the performance of a chemiluminometric immunoassay to detect Chlamydia trachomatis antigens in centrifuged first void urine and urethral swab samples from menSex Transmitted DisYear: 19921931531910.1097/00007435-199211000-00003
Lee HH,Chernesky MA,Schachter J,Burczak JD,Andrews WW,Muldoon S,Leckie G,Stamm WE,Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urineLancetYear: 199534521321610.1016/S0140-6736(95)90221-X7823713
Mahony JB,Chernesky MA,Effect of swab type and storage temperature on the isolation of Chlamydia trachomatis from clinical specimensJ Clin MicrobiolYear: 1985228658673902883
Mårdh P,Zeeberg B,Toxic effect of sampling swabs and transportation test tubes on the formation of intracytoplasmic inclusions of Chlamydia trachomatis in McCoy cell culturesBr J Vener DisYear: 1981572682726268242
Ngeow YF,Limitations of serodiagnosis in chlamydial genital tract infectionsAnn Acad Med SingaporeYear: 1996253003048799029
Wang ZY,Fu GY,Chen RF,Qin Y,Fast diagnosis reagent for genital tract Chlamydia trachomatisYear: 2005China: CN patent 1217004C
Cheng A,Qian Q,Kirby JE,Evaluation of the Abbott RealTime CT/NG assay in comparison to the Roche cobas amplicor CT/NG assayJ Clin MicrobiolYear: 2011491294130010.1128/JCM.02595-1021325546
Cosentino LA,Landers DV,Hillier SL,Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimensJ Clin MicrobiolYear: 2003413592359610.1128/JCM.41.8.3592-3596.200312904360
Jalal H,Al-Suwaine A,Stephen H,Carne C,Sonnex C,Comparative performance of the Roche COBAS Amplicor assay and in-house real-time PCR assay for diagnosis of Chlamydia trachomatis infectionJ Med MicrobiolYear: 20075632032210.1099/jmm.0.46762-017314360
Kerndt P,Ferrero DV,Aynalem G,Monga D,Wang S,Zhang N,Wong C,Liggins M,Meng Q,First report of performance of the versant CT/GC DNA 1.0 Assay (kPCR) for detection of Chlamydia trachomatis and Neisseria gonorrhoeaeJ Clin MicrobiolYear: 2011491347135310.1128/JCM.01634-1021307209
Moller JK,Pedersen LN,Persson K,Comparison of the Abbott RealTime CT new formulation assay with two other commercial assays for detection of wild-type and new variant strains of Chlamydia trachomatisJ Clin MicrobiolYear: 20104844044310.1128/JCM.01446-0920007394
Pedersen LN,Pødenphant L,Møller JK,Highly discriminative genotyping of Chlamydia trachomatis using omp1 and a set of variable number tandem repeatsClin Microbiol InfectYear: 20081464465210.1111/j.1469-0691.2008.02011.x18558936
Greenwell P,Kakourou G,Raghooputh S,Analysis of glycosidases activity in Chlamydia trachomatis L2 SerotypeInt J med UpdateYear: 200612532
Siriwardena A,Strachan H,El-Daher S,Way G,Bryan W,Glushka J,Moremen K,Boons GJ,Potent and selective inhibition of class II α-D-mannosidase activity by a bicyclic sulfonium saltChemBioChemYear: 2005684584810.1002/cbic.20040039715800866
Skudlarek MD,Orgebin-Crist MC,Effect of swainsonine on rat epididymal glycosidasesJ Reprod FertYear: 19888461161710.1530/jrf.0.0840611
Tulsiani DR,Glycan-modifying enzymes in luminal fluid of the mammalian epididymis: an overview of their potential role in sperm maturationMol Cell EndocrinolYear: 2006250586510.1016/j.mce.2005.12.02516413674
Vázquez-Reyna AB,Balcázar-Orozco R,Flores-Carreón A,Biosynthesis of glycoproteins in Candida albicans: biochemical characterization of a soluble alpha-mannosidaseFEMS Microbiol LettYear: 19931063213258454197
Tulsiani DR,Skudlarek MD,Orgebin-Crist MC,Human sperm plasma membranes possess alpha-D-mannosidase activity but no galactosyltransferase activityBiol ReprodYear: 19904284385810.1095/biolreprod42.5.8432116923
Gao X,Chen XS,Yin YP,Zhong MY,Shi MQ,Wei WH,Chen Q,Peeling RW,Mabey D,Distribution study of Chlamydia trachomatis serovars among high-risk women in china performed using PCR-restriction fragment length polymorphism genotypingJ Clin MicrobiolYear: 20074510851089

[TableWrap ID: T1] Table 1 

Reference strains and cell line

Strains or cell line Accession numbers Organizations
Acinetobacter baumannii
Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida albicans
Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida glabrata
Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida guilliermondii
Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida krusei
Harmony Biotechnology Co., Ltd (Shanghai, China)
Cryptococcus neoformans
China Medical Microbiological Culture Collection Center (fungi)(Nanjing, China)
Candida parapsilosis
China General Microbiological Culture Collection Center (Beijing, China)
Candida tropicalis
Harmony Biotechnology Co., Ltd (Shanghai, China)
Chlamydia trachomatis Serovar D
American Type Culture Collection(Manassas, USA)
Enterococcus faecalis
Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Enterococcus faecium
Harmony Biotechnology Co., Ltd (Shanghai, China)
Escherichia coli
Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
Gardnerella vaginalis
Harmony Biotechnology Co., Ltd (Shanghai, China)
Haemophilus influenzae
Harmony Biotechnology Co., Ltd (Shanghai, China)
Klebsiella pneumoniae
Tianhe Microorganism Reagent Co., Ltd (Hangzhou, China)
American Type Culture Collection(Manassas, USA)
Mycoplasma hominis
Harmony Biotechnology Co., Ltd (Shanghai, China)
Neisseria gonorrhoeae
Henan Provincial Center for Disease Control and Prevention (Zhengzhou, China)
Pseudomonas aeruginosa
Land Bridge Biotechnology Co., Ltd (Beijing, China)
Proteus mirabilis
Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Salmonella enteritidis
Land Bridge Biotechnology Co., Ltd (Beijing, China)
Staphylococus aureus
Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
Staphylococcus aureus
Capital Institute of Pediatrics (Beijing, China)
Staphylococcus epidermidis
Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Staphylococus saprophyticus
Land Bridge Biotechnology Co., Ltd (Beijing, China)
Stenotrophomonas maltophilia
Land Bridge Biotechnology Co., Ltd (Beijing, China)
Streptococus agalactiae
Harmony Biotechnology Co., Ltd (Shanghai, China)
Streptococus pneumoniae
National Center for Clinical Laboratory (Beijing, China)
Streptococus pyogenes
Harmony Biotechnology Co., Ltd (Shanghai, China)
Trichomonas vaginalis
Harmony Biotechnology Co., Ltd (Shanghai, China)
Ureaplasma urealyticum ATCC15531 Harmony Biotechnology Co., Ltd (Shanghai, China)

[TableWrap ID: T2] Table 2 

Composition of LMA for Mycoplasma (per liter) *

Ingredient Concentration Ingredient Concentration
6.4 g
Beef heart extract power
7.2 g
112 mg
Yeast extract power
2.72 g
80 mg
8.0 g
80 mg
Horse serum
200 ml
320 mg
Penicillin sodium
1,000,000 units
122 mg
Ampicillin sodium
375 mg
48 mg
40 mg
Cysteine hydrochloride
0.8 g
Polymyxin B
40,000 units
Arginine hydrochloride
4.0 g
15,000 USP units
Urea 4.0 g    

*Adjusted to pH 6.25.

[TableWrap ID: T3] Table 3 

The media and culture methods for bacteria and candida

Strains Media Temp. Time
A. baumannii, E. faecalis,
Blood agar base a
24 h
E. faecium, E. coli, K. pneumoniae,
P. mirabilis, P. aeruginosa,
S. enteritidis, S. aureus,
S. epidermidis, S. saprophyticus,
S. maltophilia, S. agalactiae,
S. pyogenes, S. pneumoniae
G. vaginalis *
Blood agar base
48 h
H. influenzae *
Thayer Martin media b
24 h
N. gonorrhoeae *
48 h
C. albicans, C. tropicalis,
Sabouraud dextrose agar c 37°C
24 h
C. glabrata, C. parapsilosis,
C. guilliermondii, C. krusei,
C. neoformans 30°C 48 h

a,b,c Oxoid, Basingstoke, UK; a supplemented with 5% sheep blood; b supplemented with 5% horse blood; * cultured in a candle jar.

[TableWrap ID: T4] Table 4 

C. trachomatis detection results of 553 cases with culture, LCR and enzymatic method used an expanded gold standard as the reference standard

Method No. of true positives/positives No. of true negatives/negatives
Enzymatic method
Urethral discharge 22/24
Urethral discharge 126/127
Prostate massage liquid 8/47
Prostate massage liquid 4/5
Cervical secretion 31/33
Cervical secretion 196/199
Vaginal secretion 25/28
Vaginal secretion 87/90
Cell culture
Urethral discharge 18/18
Urethral discharge 128/133
Prostate massage liquid 7/7
Prostate massage liquid 43/45
Cervical secretion 21/21
Cervical secretion 198/211
Vaginal secretion 14/14
Vaginal secretion 90/104
Urethral discharge 22/22
Urethral discharge 128/133
Prostate massage liquid 8/8
Prostate massage liquid 43/45
Cervical secretion 32/32
Cervical secretion 198/211
Vaginal secretion 27/27
Vaginal secretion 90/104
Expanded gold standard
Urethral discharge 23
Urethral discharge 128
Prostate massage liquid 9
Prostate massage liquid 43
Cervical secretion 34
Cervical secretion 198
  Vaginal secretion 28 Vaginal secretion 90

[TableWrap ID: T5] Table 5 

Clinical performances of three assays for C. trachomatis using specimens included prostate massage liquid

Methods % Sensitivity (95% CI) % Specificity (95% CI)
Enzymatic methoda
91.5 (85.9, 97.1)
90.0 (87.3, 92.7)
Cell cultureb
63.8 (54.1, 73.5)
100.0 (100.0, 100.0)
LCRc 94.7 (90.2, 99.2) 100.0 (100.0, 100.0)

a Χ2 = 8.030, P = 0.005, P < 0.05; b Χ2 = 8.721, P = 0.003, P < 0.05; c Χ2 = 0.164, P = 0.685, P > 0.05.

[TableWrap ID: T6] Table 6 

Clinical performances of three assays for C. trachomatis using specimens excluded prostate massage liquid

Methods % Sensitivity (95% CI) % Specificity (95% CI)
Enzymatic methoda
91.8 (86.0, 97.6)
98.3 (97.1, 99.5)
Cell cultureb
64.6 (54.3, 74.9)
100.0 (100.0, 100.0)
LCRc 95.3 (90.8, 99.8) 100.0 (100.0, 100.0)

a Χ2 = 0, P = 1, P > 0.05; b Χ2 = 8.605, P = 0.003, P < 0.05; c Χ2 = 0.116, P = 0.734, P > 0.05.

Article Categories:
  • Research Article

Keywords: Chlamydia trachomatis, α-mannosidase, Activity, Gold standard, Marker.

Previous Document:  Power of the policy: how the announcement of high-stakes clinical examination altered OSCE implement...
Next Document:  Protective effect of transparent film dressing on proton therapy induced skin reactions.